AGP Executive Report
Last update: 10 hours agoRSV Prevention: EU regulators have backed expanding Merck’s ENFLONSIA to protect high-risk children under two through a second RSV season. The European Commission’s decision, covering Liechtenstein, is expected within two months. Cancer Treatment: The EMA has recommended belzutifan plus lenvatinib for adults with advanced kidney cancer after prior immunotherapy; the European Commission will decide on approval, including for Liechtenstein, in the coming months. Short Bowel Syndrome: The European Commission has approved Zealand Pharma’s Zeydovio for adults with the condition, introducing a new twice-weekly treatment option in Europe. Public Health Surveillance: The ECDC is preparing a multilingual platform to help countries detect and assess emerging health threats, with rollout planned next year.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.